Chemo-proof T cells

T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven’t produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant γδ T cells with chemotherapy, Incysus Ltd. has hit upon a strategy that may be safer and more effective against solid tumors than conventional T cell therapies.

The αβ T cells most T cell therapies use are antigen-specific and may not eliminate the entire tumor. Incysus relies on γδ T cells because they do not require antigen processing to detect target cells, and they penetrate and kill solid tumors more effectively than αβ cells. ...